论文部分内容阅读
目的 探讨术前化疗对晚期卵巢癌预后的影响。方法 将曾行肿瘤细胞减灭术的晚期上皮性卵巢癌患者按照术前是否化疗分为两组,进行回顾性分析,比较两组患者与预后有关的指标及生存情况。结果 1990年1月至1998年12月,收治Ⅲc期、Ⅳ期上皮性卵巢癌患者,并施行了肿瘤细胞减灭术者共71例。其中术前化疗组26例,术前未化疗组45例。两组患者手术范围基本相同。术前化疗组期别晚、分级高,预后不良的组织病理类型所占比例高,但治疗结果两组间达到满意肿瘤细胞减灭术的比例无明显差别。追踪随访术前化疗组及未化疗组,5年存活率分别为30.72％及40.60％(P>0.05)。结论 对术前估计难以达到满意的肿瘤细胞减灭术的晚期卵巢癌患者,术前化疗有可能提高生存率。
Objective To investigate the effect of preoperative chemotherapy on the prognosis of advanced ovarian cancer. Methods Patients with advanced epithelial ovarian cancer who underwent cytoreductive surgery were divided into two groups according to whether they were treated with chemotherapy or not before surgery. The prognosis-related indicators and survival were compared between the two groups. Results From January 1990 to December 1998, 71 patients with stage Ⅲc and Ⅳ epithelial ovarian cancer were treated and tumor cytoreductive surgery was performed. Among them, 26 cases were preoperative chemotherapy group and 45 cases were preoperative chemotherapy group. The two groups of patients with the same surgical range. The proportion of histopathological types with high grade and poor prognosis was high in preoperative chemotherapy group, but there was no significant difference in the proportion of satisfactory cytoreductive surgery between the two groups. The 5-year survival rates were 30.72% and 40.60%, respectively (P> 0.05). Conclusion Preoperative chemotherapy may increase the survival rate of patients with advanced ovarian cancer who are difficult to achieve satisfactory cytoreductive surgery before surgery.